- Home
- PESI vs EDIT Comparison
PESI vs EDIT Comparison
Compare PESI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- EDIT
- Stock Information
- Founded
- PESI 1990
- EDIT 2013
- Country
- PESI United States
- EDIT United States
- Employees
- PESI N/A
- EDIT N/A
- Industry
- PESI Environmental Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PESI Industrials
- EDIT Health Care
- Exchange
- PESI Nasdaq
- EDIT Nasdaq
- Market Cap
- PESI 195.2M
- EDIT 176.7M
- IPO Year
- PESI 1992
- EDIT 2016
- Fundamental
- Price
- PESI $11.38
- EDIT $1.35
- Analyst Decision
- PESI Strong Buy
- EDIT Buy
- Analyst Count
- PESI 1
- EDIT 14
- Target Price
- PESI $18.00
- EDIT $8.08
- AVG Volume (30 Days)
- PESI 196.2K
- EDIT 3.2M
- Earning Date
- PESI 11-13-2024
- EDIT 11-04-2024
- Dividend Yield
- PESI N/A
- EDIT N/A
- EPS Growth
- PESI N/A
- EDIT N/A
- EPS
- PESI N/A
- EDIT N/A
- Revenue
- PESI $67,134,000.00
- EDIT $61,759,000.00
- Revenue This Year
- PESI N/A
- EDIT N/A
- Revenue Next Year
- PESI $47.99
- EDIT N/A
- P/E Ratio
- PESI N/A
- EDIT N/A
- Revenue Growth
- PESI N/A
- EDIT 150.95
- 52 Week Low
- PESI $7.38
- EDIT $1.33
- 52 Week High
- PESI $16.25
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- PESI 34.17
- EDIT 24.44
- Support Level
- PESI $11.44
- EDIT $1.39
- Resistance Level
- PESI $12.13
- EDIT $2.37
- Average True Range (ATR)
- PESI 0.71
- EDIT 0.18
- MACD
- PESI -0.14
- EDIT -0.05
- Stochastic Oscillator
- PESI 21.34
- EDIT 1.44
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: Treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.